Novo Nordisk Intends to Appeal Adverse Ruling in Prandin (repaglinide) Patent Case

Novo Nordisk announced it would appeal the US District Court for the Eastern District of Michigan’s ruling regarding Novo Nordisk’s US patent covering combination drugs Prandin and PrandiMet. The district court ruled that the patent, which covers the combination use of repaglinide and metformin for the treatment of type 2 diabetes, is invalid and unenforceable.

Novo Nordisk markets repaglinide under the trade name Prandin and a fixed dose repaglinide/metformin tablet under the trade name PrandiMet. The district court ruling has the potential to facilitate launch of a generic repaglinide. At present, it is unclear whether or when a generic version of Prandin or PrandiMet will be available in the US market.

ASweetLife Team

FDA Approves First GLP-1 Pill, Novo Nordisk’s Rybelsus TheU.S. FDA has approved Rybelsus (semaglutide), the first and only glucagon-like peptide-1 (GLP-1) analog in a pill. “GLP-1 receptor agonists are effective medications for people with type 2 diabetes but have…
Gary Taubes' Case for the Keto Diet: A Book Review “We believe than an injustice is being perpetrated that has to be righted.” Gary Taubes doesn’t mince words in his new book, The Case for Keto. The text is his…
The Case for Keto: An Interview with Gary Taubes Gary Taubes is an investigative journalist, not a doctor, but he may be the world’s most significant advocate for ketogenic and low-carbohydrate diets. Taubes’ reporting over the last two decades…
The Case for Using Regular (R) Insulin As a teen athlete with Type 1 diabetes, I achieve normal blood sugars using a few key tricks from Dr. Bernstein. One of the most important of these tricks I…